Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
SVB Leerink
Pharma
ESMO preview: What to expect from Keytruda-Padcev combo?
Do Keytruda's recent clinical failures mean the PD-1 king has reached a bottleneck? And, is the closely watched Cohort K a sure win?
Angus Liu
Sep 7, 2022 10:36am
Reaction 'excessive' to Sanofi's upcoming litigation: analysts
Aug 11, 2022 11:12am
Roche's Vabysmo to take a bite out of sales of Eylea, SVB says
Jul 25, 2022 10:37am
Nods for two gene therapies 'absolutely critical' for bluebird
Mar 7, 2022 9:22am
BMS, Amgen and Pfizer face steepest patent cliffs
Dec 29, 2021 9:56am
Large pharmas will have $1.7T M&A firepower next year: analyst
Dec 1, 2021 11:05am
